SUNNYVALE, Calif., Oct. 10 /PRNewswire/ -- Scios Inc. today announced that
the company has launched a first-of-its-kind nationwide registry to collect
and analyze demographic and treatment data about patients hospitalized due to
acutely decompensated heart failure.
ADHERE, the Acute Decompensated HEart failure national REgistry, is
expected to have a unique database of information of tens of thousands of
patients gathered from approximately 200 hospitals over the next several
years. ADHERE is overseen by an independent scientific advisory committee of
nationally recognized heart failure experts.
Scios created ADHERE to help clinicians better determine factors
associated with improved clinical outcomes in acute decompensated heart
failure, the primary cause of more than one million hospital admissions in the
U.S. each year.
"While acute heart failure is a leading cause of hospitalizations and
heart failure is the single largest expense for Medicare, information and
evidence-based treatment guidelines have been scarce for this fast-growing
medical condition," said Gregg Fonarow, M.D., Director, Ahmanson-UCLA
Cardiomyopathy Center, University of California, Los Angeles and member of
ADHERE's scientific advisory committee. "Current heart failure treatment
guidelines are drawn from data on stable outpatients. There simply needs to
be more data on patients hospitalized with acute heart failure, why they are
admitted to the hospital, and what the optimal treatment strategy is. ADHERE
will provide comprehensive demographic and treatment data on a wide range of
hospitalized heart failure patients. By tracking how these very sick patients
are treated over time, we can use this information to identify optimal
treatment strategies for them and develop comprehensive acute heart failure
guidelines."
Roughly five million Americans suffer from heart failure, with 550,000 new
cases diagnosed each year. There are approximately one million
hospitalizations each year in the United States attributable specifically to
acutely decompensated heart failure, which cost the healthcare system
$15 billion annually. Another two million Americans are hospitalized each
year with CHF as the secondary diagnosis. In the U.S., heart failure
represents the most common cause of hospitalizations for patients over age
65.
In ADHERE, acute care hospitals across the United States will contribute
data securely while maintaining patient anonymity. Information will be
collected on patient demographics, medical history, initial evaluation,
hospital treatment and medications, resource utilization, procedures and
disposition. ADHERE will assist hospitals with their internal quality
improvement efforts by providing customized benchmark reports enabling each
hospital to compare characteristics of its patient case-mix and its patient
evaluation and treatment practices with those of similar groups of hospitals,
regionally and nationally.
Members of the ADHERE Scientific Advisory Committee include: William
Abraham, M.D., Division of Cardiovascular Medicine, University of Kentucky
College of Medicine, Lexington, KY; Kirkwood Adams, Jr., M.D., Division of
Cardiology, University of North Carolina, Chapel Hill, N.C.; Maria Rosa
Costanzo, M.D., Professor of Medicine, Rush Medical Center, Chicago, IL;
Teresa DeMarco, M.D., Division of Cardiology, University of California, San
Francisco, CA; Charles Emerman, M.D., Department of Emergency Medicine, The
Cleveland Clinic Foundation, Cleveland, OH; Gregg Fonarow, M.D., Ahmanson-UCLA
Cardiomyopathy Center, University of California, Los Angeles, CA; Maria
Galvao, CANP, Department of Cardiology, Montefiore Medical Center, New York,
NY; and Thierry LeJemtel, M.D., Cardiology Division, Albert Einstein Hospital,
New York, NY.
If you are interested in participating in the ADHERE registry, please send
a message to adhereinfo@sciosinc.com.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "believe," "intend," "expect," "may," "should," "plan,"
"project," "contemplate," "anticipate" or similar statements. Statements that
are not historical facts are forward-looking statements based on current
assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of our pipeline products, including SCIO-469, as
well as other risks detailed from time to time in the reports filed by Scios
with the SEC, including the Company's quarterly reports and annual report on
Form 10-K. Actual results, performance or achievements of Scios may differ
significantly from those described in these forward-looking statements. Scios
disclaims any intention or obligation to update or revise any financial
projections or forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Wendy Carhart of Scios Inc., +1-408-616-8325;
or media, Jim Weiss of Weisscomm, +1-415-389 5055; or Tez Termulo
of Edelman Public Relations, +1-212-704-8102, for Scios Inc.
|
